The next frontier (or one of many?) on the cancer screening and over diagnosis debate, this time for esophageal cancer. The pattern is familiar, a new less expensive technology is developed, business practices and models provide incentives to create demand, organizations note the lack of justification for expanded screening, and interest groups spring up advocating for increased screening. Quote:
“The unfortunate thing is … this is something that will be a money-maker for the people who offer it,” says Brawley of the American Cancer Society. In the absence of research showing that routine screening yields clear benefits, it’s premature to be doing it, “especially if they are charging for the procedure,” he says.
“This is marketing, that is all that is,” says Dr. H. Gilbert Welch, an internist at the Dartmouth Institute for Health Policy and Clinical Practice in Hanover, New Hampshire, and author of “Overdiagnosed: Making People Sick in the Pursuit of Health.”